Cancer Research Insights & Advancements

Explore updates on our innovative clinical trials, advancements in cancer research, fundraising efforts and the latest developments in oncology.

For media inquiries: media@marycrowley.org

Sort By

MARY CROWLEY NEWSLETTER: VOLUME 8 ISSUE 2

PINK BARGE DOCKS IN CATOOSA TO SHARE MESSAGE OF HOPE

CATOOSA, Okla. (KTUL) -- An unusual site docked at the Port of Catoosa; a pink barge.

MARY CROWLEY NEWSLETTER: VOLUME 8 ISSUE 1

MARY CROWLEY NEWSLETTER: VOLUME 7 ISSUE 4

EFFECTS OF ALISERTIB, AN INVESTIGATIONAL AURORA A KINASE INHIBITOR ON THE QTC INTERVAL IN PATIENTS WITH ADVANCED MALIGNANCIES.

Zhou X, Nemunaitis J, Pant S, Bauer TM, Patel M, Sarantopoulos J, Lockhart AC, Goodman D, Huebner D, Mould DR, Venkatakrishnan K. Effects of Alisertib, an investigational Aurora A kinase inhibitor on the QTc interval in patients with advanced malignancies. Investigational New Drugs. 2017 Aug 18 [Epub ahead of print].

HARNESSING THE IMMUNE RESPONSE TO TARGET TUMORS

Manning L, Nemunaitis J. Harnessing the immune response to target tumors. Faculty of 1000. 2017 May 18;6:710. doi: 10.12688/f1000research.10795.1. eCollection 2017. Review.

A FIRST-IN-HUMAN, PHASE I, DOSE-ESCALATION STUDY OF TAK-117, A SELECTIVE PI3KΑ ISOFORM INHIBITOR, IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES

Juric D, de Bono J, LoRusso P, Nemunaitis J, Heath EI, Kwak EL, Mercade TM, Geuna E, de Miguel-Luken MJ, Patel C, Kuida K, Sankoh S, Westin E, Zohren F, Shou Y, Tabernero J. A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 2017 Sept 1;23(17):5015-5023.

SAFETY, TRAFFICKING AND ANTITUMOR ACTIVITY OF CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS SPECIFIC FOR TAG-72 IN PATIENTS WITH METASTATIC COLORECTAL CANCER

Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. Safety, Trafficking and Antitumor Activity of Chimeric Antigen Receptor (CAR)-T Cells Specific for TAG-72 in Patients with Metastatic Colorectal Cancer. Journal for Immunotherapy of Cancer. 2017 Mar 21; 5-22. eCollection 2017.

IMMUNE CHECKPOINT INHIBITOR ELICITED COMPLETE RESPONSE IN A HEAVILY PRETREATED PATIENT WITH METASTATIC ENDOMETRIAL CARCINOMA WITH A HIGH TUMOR MUTATION BURDEN (TMB)

Barve M, Adams N, Plato L, Dupler R, Anand R, Jones J, Brown M, Stephens PJ, Shiller SM, Senzer N, Nemunaitis J. Case Report: Immune Checkpoint Inhibitor Elicited Complete Response in a Heavily Pretreated Patient with Metastatic Endometrial Carcinoma with a High Tumor Mutation Burden (TMB). Molecular Medicine. 2017 Dec 6; 1(1):005.

Pages: 12345678910111213141516171819202122232425262728293031

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.

7777 Forest Lane,
Building C-707
Dallas, TX 75230

972.566.3000

For media inquiries: media@marycrowley.org

Cancer Research Insights & Advancements

Subscribe to Our Newsletter

Connect With Us